Position in NVS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$382,240
+$2,198 QoQ
Shares Held
2,439
-2.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#1,008
of 1,603 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026M. Kulyk & Associates, LLC holds $37,765,981 across 8 Drug Manufacturers - General names. NVS ranks #7 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
94,863 | $12,189,895 | |
| 2 | LLY |
ELI LILLY & Co
|
7,945 | $9,529,472 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
74,859 | $9,457,686 | |
| 4 | NVO |
Novo Nordisk A S
|
93,400 | $4,477,596 | |
| 5 | ABBV |
AbbVie Inc.
|
3,846 | $967,807 | |
| 6 | JNJ |
Johnson & Johnson
|
1,941 | $492,955 | |
| 7 | NVS |
Novartis AG
This page
|
2,439 | $382,240 | |
| 8 | AMGN |
Amgen Inc
|
741 | $268,330 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $382,240 | 2,439 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $380,042 | 2,488 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $280,703 | 2,036 | Shares | Sole | 2026-01-08 | |
| 2025-09-30 | $253,915 | 1,980 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $286,793 | 2,370 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $248,154 | 2,226 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $233,349 | 2,398 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $271,217 | 2,358 | Shares | Sole | 2024-11-07 | |
| 2024-06-30 | $248,051 | 2,330 | Shares | Sole | 2024-08-05 | |
| No filing history on record for this holder in this stock. | ||||||